Form 4: Glaukos Director Leana Wen Reports Significant Equity Grants and Increased Beneficial Ownership

Glaukos Corporation Director Leana Wen has reported the acquisition of additional restricted stock units and stock options, increasing her beneficial ownership in the company.

Summary

• Leana Wen, a Director at Glaukos Corp (GKOS), reported changes in her beneficial ownership of company securities.
• On January 2, 2025, Ms. Wen received a grant of 461 restricted stock units (RSUs) in lieu of annual director retainer fees, which will vest in full on January 2, 2026.
• On May 29, 2025, she received an additional grant of 2,108 restricted stock units (RSUs) pursuant to the Issuer's Director Compensation Policy, vesting in full on May 29, 2026.
• Also on May 29, 2025, Ms. Wen was granted 3,149 stock options with an exercise price of $94.87, which will vest in full on May 29, 2026, and expire on May 29, 2035.
• Following the January 2, 2025 transaction, Ms. Wen's beneficial ownership of common stock was 18,708 shares, including 2,177 unvested RSUs and deferred vested RSUs.
• Following the May 29, 2025 transactions, her beneficial ownership of common stock increased to 20,816 shares, including 4,285 unvested RSUs and deferred vested RSUs.
• Her beneficial ownership of derivative securities (stock options) is 3,149 following the reported transactions.

Sentiment

Score: 7

Explanation: The document reports routine equity compensation grants to a director, which is generally a positive sign of alignment between management and shareholders, but does not contain significant new operational or financial news to warrant a higher score. It's a standard, expected disclosure.

Positives

• The director's compensation structure includes equity grants, aligning her interests with shareholders.
• Increased beneficial ownership by a director signals confidence in the company's future performance.
• The grants are part of a standard Director Compensation Policy, indicating a structured approach to executive incentives.

Future Outlook

This Form 4 filing details past and future equity grants and vesting schedules for a director, reflecting standard compensation practices rather than providing a forward-looking business outlook.

Industry Context

This filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard director compensation practices within the medical technology or ophthalmology industry, where equity-based incentives are frequently used to align director interests with long-term company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a common practice across various industries, including medical technology, aligning director incentives with shareholder value.
• The vesting schedule of one year for these equity grants is typical for director compensation, promoting retention and long-term commitment.
• The exercise price of $94.87 for the stock options is based on the market price at the time of grant, which is standard for compensatory option grants.

Related Party Transactions

• The grants of restricted stock units and stock options to Director Leana Wen are considered related party transactions as they involve compensation from the issuer to a member of its board of directors, conducted under the Issuer's Director Compensation Policy.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing, as it pertains specifically to director compensation.

Next Steps

• The restricted stock units granted on January 2, 2025, are expected to vest on January 2, 2026.
• The restricted stock units and stock options granted on May 29, 2025, are expected to vest on May 29, 2026.

Key Dates

Recommendation

Keywords

Glaukos Corp, GKOS, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Beneficial Ownership, Equity Grants